{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:16:07Z","timestamp":1789776967561,"version":"4.0.1"},"reference-count":98,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Among emergent climate-sensitive infectious diseases, some mosquito-vectored arbovirus infections have epidemiological, social, and economic effects. Dengue virus (DENV), West Nile virus (WNV), and Chikungunya virus (CHIKV) disease, previously common only in the tropics, currently pose a major risk to global health and are expected to expand dramatically in the near future if adequate containment measures are not implemented. The lack of safe and effective vaccines is critical as it seems likely that emerging mosquito-vectored arbovirus infections will be con-trolled only when effective and safe vaccines against each of these infections become available. This paper discusses the clinical characteristics of DENV, WNV, and CHIKV infections and the state of development of vaccines against these viruses. An ideal vaccine should be able to evoke with a single administration a prompt activation of B and T cells, adequate concentrations of protecting\/neutralizing antibodies, and the creation of a strong immune memory capable of triggering an effective secondary antibody response after new infection with a wild-type and\/or mutated infectious agent. Moreover, the vaccine should be well tolerated, safe, easily administrated, cost-effective, and widely available throughout the world. However, the development of vaccines against emerging mosquito-vectored arbovirus diseases is far from being satisfactory, and it seems likely that it will take many years before effective and safe vaccines for all these infections are made available worldwide.<\/jats:p>","DOI":"10.3390\/vaccines12010087","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:15:01Z","timestamp":1705317301000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Development of Vaccines against Emerging Mosquito-Vectored Arbovirus Infections"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10661-023-11856-9","article-title":"Interactions of urbanisation, climate variability, and infectious disease dy-namics: Insights from the Coimbatore district of Tamil Nadu","volume":"195","author":"Suresh","year":"2023","journal-title":"Environ. Monit. Assess."},{"key":"ref_2","first-page":"100701","article-title":"Decision-support tools to build climate resilience against emerging infectious diseases in Europe and beyond","volume":"32","author":"Semenza","year":"2023","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Miranda, A.V., Lestari, B.W., Indrarini, A., Arsy, F.F., Sagala, S., Bisri, M.B.F., and Lucero-Prisno, D.E. (2023). Adaptation of health systems to climate change-related infectious disease outbreaks in the ASEAN: Protocol for a scoping review of national and regional policies. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0286869"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Massengo, N.R.B., Tinto, B., and Simonin, Y. (2023). One Health Approach to Arbovirus Control in Africa: Interests, Challenges, and Difficulties. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061496"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"taad062","DOI":"10.1093\/jtm\/taad062","article-title":"Climate change and vector-borne diseases: A multi-omics approach of temperature-induced changes in the mosquito","volume":"30","author":"Bellone","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.pcl.2023.03.012","article-title":"Climate Change and Child Health Equity","volume":"70","author":"Budolfson","year":"2023","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20130553","DOI":"10.1098\/rstb.2013.0553","article-title":"Evolution in action: Climate change, biodiversity dynamics and emerging infectious disease","volume":"370","author":"Hoberg","year":"2015","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2542-5196(21)00132-7","article-title":"Projecting the risk of mosquito-borne diseases in a warmer and more populated world: A multi-model, multi-scenario intercomparison modelling study","volume":"5","author":"Sewe","year":"2021","journal-title":"Lancet Planet Health"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ryan, S.J., Carlson, C.J., Mordecai, E.A., and Johnson, L.R. (2019). Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl. Trop Dis., 13.","DOI":"10.1371\/journal.pntd.0007213"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13071-019-3591-8","article-title":"Second WIN International Conference on \"Integrated approaches and innovative tools for combating insecticide resistance in vectors of arboviruses\", October 2018, Singapore","volume":"12","author":"Corbel","year":"2019","journal-title":"Parasites Vectors"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1056\/NEJMoa2030243","article-title":"Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue","volume":"384","author":"Utarini","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","first-page":"5","article-title":"Antivirals against (Re)emerging Flaviviruses: Should We Target the Virus or the Host?","volume":"13","author":"Saiz","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vuitika, L., Prates-Syed, W.A., Silva, J.D.Q., Crema, K.P., C\u00f4rtes, N., Lira, A., Lima, J.B.M., Camara, N.O.S., Schimke, L.F., and Cabral-Marques, O. (2022). Vaccines against Emerging and Neglected Infectious Diseases: An Overview. Vaccines, 10.","DOI":"10.3390\/vaccines10091385"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vac-cination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","unstructured":"European Center for Disease Prevention and Control (2023, September 20). Dengue Worldwide Overview. Available online: https:\/\/www.ecdc.europa.eu\/en\/dengue-monthly#:~:text=In%202023%2C%20and%20as%20of,have%20been%20reported%20in%20Europe."},{"key":"ref_16","unstructured":"World Health Organization (2023, September 20). Dengue and Severe Dengue. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_17","unstructured":"European Center for Disease Prevention and Control (2023, September 20). Increasing Risk of Mosquito-Borne Diseases in EU\/EEA Following Spread of Aedes Species. Available online: https:\/\/www.ecdc.europa.eu\/en\/news-events\/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2200818","DOI":"10.2807\/1560-7917.ES.2022.27.44.2200818","article-title":"Autochthonous dengue in mainland France, 2022, geographical extension and incidence increase","volume":"27","author":"Cochet","year":"2022","journal-title":"Euro. Surveill."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2001606","DOI":"10.2807\/1560-7917.ES.2020.25.36.2001606","article-title":"First autochthonous dengue outbreak in Italy, August 2020","volume":"25","author":"Lazzarini","year":"2020","journal-title":"Euro. Surveill."},{"key":"ref_20","unstructured":"Istituto di Sanit\u00e0 (2023, September 20). Febbre Dengue. Available online: https:\/\/www.epicentro.iss.it\/febbre-dengue\/aggiornamenti."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1038\/s41598-023-34349-8","article-title":"Analysis of the correlation between climatic variables and Dengue cases in the city of Alagoinhas\/BA","volume":"13","author":"Figueredo","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lenharo, M. (2023). Dengue is making records in the Americas\u2014What\u2019s behind the surge?. Nature.","DOI":"10.1038\/d41586-023-02423-w"},{"key":"ref_23","unstructured":"Florida Health (2023, September 20). Florida Arborvirus Surveillance, Available online: https:\/\/www.floridahealth.gov\/diseases-and-conditions\/mosquito-borne-diseases\/_documents\/2023-week31-arbovirus-surveillance-report.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17485","DOI":"10.1038\/s41598-023-44559-9","article-title":"Early biomarkers for prediction of severe manifestations of dengue fever: A systematic review and a meta-analysis","volume":"13","author":"Moallemi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/infdis\/jiaa603","article-title":"Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial","volume":"223","author":"Lin","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am. J. Trop Med. Hyg."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Malik, S., Ahsan, O., Mumtaz, H., Tahir Khan, M., Sah, R., and Waheed, Y. (2023). Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies. Vaccines, 11.","DOI":"10.3390\/vaccines11081328"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiaa351","article-title":"A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain","volume":"223","author":"Endy","year":"2021","journal-title":"J. Infect Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1016\/j.vaccine.2015.09.053","article-title":"Next generation dengue vaccines: A review of the preclinical development pipeline","volume":"33","author":"Vannice","year":"2015","journal-title":"Vaccine"},{"key":"ref_31","unstructured":"European Medicine Agency (2023, September 20). DEngvaxia. Available online: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dengvaxia#authorisation-details-section."},{"key":"ref_32","unstructured":"Food and Drug Administration (2023, September 20). Dengvaxia, Available online: www.fda.gov\/media\/170875\/download?attachment."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Shukla, R., Ramasamy, V., Shanmugam, R.K., Ahuja, R., and Khanna, N. (2020). Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Front Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.572681"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1128\/JVI.06335-11","article-title":"Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection","volume":"86","author":"Smith","year":"2012","journal-title":"J Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1016\/j.vaccine.2020.07.056","article-title":"Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_38","unstructured":"European Medicines Agency (2023, September 20). Qdenga. Available online: www.ema.europa.eu\/en\/documents\/assessment-report\/qdenga-epar-public-assessment-report_en.pdf."},{"key":"ref_39","unstructured":"European Medicines Agency (2023, September 20). Qdenga. Available online: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qdenga."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: A randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year Efficacy and Safety of Takeda\u2019s Dengue Vaccine Candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines is Safe and Immunogenic in Flavivirus-Naive Adults: A Randomized, Double-Blind Clinical Trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1128\/JVI.01963-10","article-title":"Phylogeography of West Nile virus: From the cradle of evolution in Africa to Eurasia, Australia, and the Americas","volume":"85","author":"May","year":"2011","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1051\/vetres\/2010039","article-title":"West Nile virus and its emergence in the United States of America","volume":"41","author":"Murray","year":"2010","journal-title":"Vet. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1099\/vir.0.046888-0","article-title":"Molecular evolution of lineage 2 West Nile virus","volume":"94","author":"McMullen","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3201\/eid1204.051379","article-title":"Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe","volume":"12","author":"Bakonyi","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3201\/eid1402.070457","article-title":"Genetic determinants of virulence in patho-genic lineage 2 West Nile virus strains","volume":"14","author":"Botha","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3201\/eid0704.017403","article-title":"Serologic evidence for West Nile virus in-fection in birds in the New York City vicinity during an outbreak in 1999","volume":"7","author":"Komar","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3390\/v5123021","article-title":"Vector-virus interactions and transmission dynamics of West Nile virus","volume":"5","author":"Ciota","year":"2013","journal-title":"Viruses"},{"key":"ref_52","unstructured":"Centers for Disease Control and Prevention (CDC) (2002). Intrauterine West Nile virus infection\u2014New York, 2002. MMWR. Morb. Mortal. Wkly. Rep., 51, 1135\u20131136."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Desgraupes, S., Hubert, M., Gessain, A., Ceccaldi, P.E., and Vidy, A. (2021). Mother-to-Child Transmission of Arboviruses during Breast-feeding: From Epidemiology to Cellular Mechanisms. Viruses, 13.","DOI":"10.3390\/v13071312"},{"key":"ref_54","unstructured":"Centers for Disease Control and Prevention (CDC) (2008). Detection of West Nile virus in blood donations\u2014Puerto Rico, 2007. MMWR Morb. Mortal. Wkly. Rep., 57, 577\u2013580."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2256424","DOI":"10.1080\/22221751.2023.2256424","article-title":"A virus becomes a global concern: Re-search activities on West-Nile virus","volume":"12","author":"Braun","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_56","unstructured":"Centers for Disease Control and Prevention (2023, September 20). Symptoms, Diagnosis, & Treatment, Available online: www.cdc.gov\/westnile\/symptoms\/index.html."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jama.2023.17684","article-title":"West Nile Virus Outpacing Awareness, Testing, and Reporting in the US","volume":"330","author":"Slomski","year":"2023","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/IJGM.S59902","article-title":"A review of the epidemiological and clinical aspects of West Nile virus","volume":"7","author":"Gray","year":"2014","journal-title":"Int. J. Gen. Med."},{"key":"ref_60","first-page":"6","article-title":"West Nile virus: An historical overview","volume":"5","author":"Sejvar","year":"2003","journal-title":"Ochsner J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/ijerph10083543","article-title":"Environmental Drivers of West Nile Fever Epidemiology in Europe and Western Asia\u2014A Review","volume":"10","author":"Paz","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14787210.2020.1713751","article-title":"The knowns and unknowns of West Nile virus in Europe: What did we learn from the 2018 outbreak?","volume":"18","author":"Camp","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_63","unstructured":"European Center for Disease Prevention and Control (2023, September 20). Epidemiological update: West Nile Virus Transmission Season in Europe. Available online: https:\/\/www.ecdc.europa.eu\/en\/news-events\/epidemiological-update-west-nile-virus-transmission-season-europe-2022."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/jme\/tjz151","article-title":"Introduction, Spread, and Establishment of West Nile Virus in the Americas","volume":"56","author":"Kramer","year":"2019","journal-title":"J. Med. Entomol."},{"key":"ref_65","unstructured":"Centers for Disease Control and Prevention (2023, September 20). West Nile Virus Disease Therapeutics, Available online: www.cdc.gov\/westnile\/resources\/pdfs\/WNV-therapeutics-summary-P.pdf."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kaiser, J.A., and Barrett, A.D.T. (2019). Twenty Years of Progress Toward West Nile Virus Vaccine Development. Viruses, 11.","DOI":"10.3390\/v11090823"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus","volume":"5","author":"Dayan","year":"2013","journal-title":"Viruses"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-018-0077-1","article-title":"A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen","volume":"3","author":"Wiley","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tsetsarkin, K.A., Vanlandingham, D.L., McGee, C.E., and Higgs, S. (2007). A single mutation in chikungunya virus affects vector specificity andepidemic potential. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030201"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trstmh.2007.11.013","article-title":"Resurgence of chikungunya","volume":"102","author":"Townson","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_73","unstructured":"WHO (2023, September 20). EPI-WIN Webinar: Chikungunya: Experiences from the Current Response to the Outbreak in the Americas. Available online: https:\/\/www.who.int\/news-room\/events\/detail\/2023\/05\/03\/default-calendar\/epi-win-webinar-chikungunya-experiences-from-the-current-response-to-the-outbreak-in-the-americas."},{"key":"ref_74","first-page":"199","article-title":"The Chikungunya epidemic in Italy and its re-percussion on the blood system","volume":"6","author":"Liumbruno","year":"2008","journal-title":"Blood Transfus."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4269\/ajtmh.19-0309","article-title":"Epidemiology of Dengue, Chikungunya, and Zika Virus Disease in U.S. States and Territories, 2017","volume":"101","author":"Adams","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_76","unstructured":"European Centre for Disease Prevention and Control (2023, September 20). 12 Month Chikungunya Virus Disease Case Notification Rate per 100,000 Population, August 2022 July 2023. Available online: www.ecdc.europa.eu\/en\/publications-data\/12-month-chikungunya-virus-disease-case-notification-rate-100-000-population."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/j.1537-2995.2012.03960.x","article-title":"Viremic profiles in asymptomatic and symptomatic chikungunya fever: A blood transfusion threat?","volume":"53","author":"Appassakij","year":"2013","journal-title":"Transfusion"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41426-017-0010-0","article-title":"Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community","volume":"7","author":"Auerswald","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3899\/jrheum.190162","article-title":"Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms","volume":"47","author":"Tritsch","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.2147\/DDDT.S366112","article-title":"Chikungunya Vaccine Candidates: Current Landscape and Future Prospects","volume":"16","author":"Schmidt","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenici-ty study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Whiteley, W.N., Ip, S., Cooper, J.A., Bolton, T., Keene, S., Walker, V., Denholm, R., Akbari, A., Omigie, E., and Hollings, S. (2022). Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003926"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e151095","DOI":"10.1172\/jci.insight.151095","article-title":"Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine","volume":"6","author":"Tschismarov","year":"2021","journal-title":"JCI Insight"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.omtn.2022.04.036","article-title":"A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections","volume":"28","author":"Schmidt","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"ref_87","unstructured":"Medical Professionals Reference (2023, November 12). VLP-Based Chikungunya Vaccine Highly Immunogenic in Adults, Adolescents. Available online: https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/vlp-based-chikungunya-vaccine-highly-immunogenic-in-adults-adolescents\/."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 tri-al","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: A phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bettis, A.A., L\u2019Azou Jackson, M., Yoon, I.K., Breugelmans, J.G., Goios, A., Gubler, D.J., and Powers, A.M. (2022). The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Negl. Trop Dis., 16.","DOI":"10.1371\/journal.pntd.0010069"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e160173","DOI":"10.1172\/jci.insight.160173","article-title":"Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera","volume":"7","author":"Roques","year":"2022","journal-title":"JCI Insight"},{"key":"ref_92","unstructured":"U.S. Food and Drug Administration (2023, November 12). FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-019-12444-7","article-title":"Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries","volume":"10","author":"Sharma","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20161533","article-title":"Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells","volume":"214","author":"Suan","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nri780","article-title":"Ethical issues for vaccines and immunization","volume":"2","author":"Ulmer","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1161149","DOI":"10.3389\/fimmu.2023.1161149","article-title":"Vaccine development for mosquito-borne viral diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kim, Y.C., and Reyes-Sandoval, A. (2023). Recent Developments in Vaccines against Flaviviruses and Alphaviruses. Vaccines, 11.","DOI":"10.3390\/vaccines11020448"},{"key":"ref_98","unstructured":"(2023, November 12). CEPI: Preparing for Future Pandemics. Available online: https:\/\/cepi.net\/."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:18Z","timestamp":1760104038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["vaccines12010087"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12010087","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}